• Alias: GW786034
    • Selectively inhibits VEGFR-1, -2, and -3, FGFR-1 and -3, KIT and PDGFR, preventing angiogenesis
    • FDA approved for renal cell carcinoma and STS
    • May also be active in ovarian cancer and NSCLC
    • Recommended dose: 800 mg daily on fasting stomach, at least 1 hour before or 2 hours after a meal; avoid grapefruit juice
    • Half-life: 31 hours
    • Metabolism: Major CYP3A4 substrate
    • Common side effects: Diarrhea, nausea/vomiting, anorexia, hypertension, hair color changes (lightening)
    • Clinical pearls: Avoid concurrent medications, which can prolong the QTc interval. Because VEGFR is inhibited, surgical intervention should e avoided.
    Other topics in Targeted and Immunotherapy Agents